uploads/2018/08/Ocrevus.png

Ocrevus Could Boost Roche’s Revenue Growth in 2018 and Beyond

By

Updated

Roche’s Neurology segment’s revenue trends

Roche’s (RHHBY) Neurology segment generated revenues of 1.38 billion Swiss francs in the first half compared to 526.0 million Swiss francs in the first half of 2017, reflecting ~164% YoY (year-over-year) growth at CER (constant exchange rates). Roche’s neuroscience portfolio includes Ocrevus and Madopar.

Article continues below advertisement

Madopar’s revenue trends

Madopar generated revenues of 182.0 million Swiss francs in the first half compared to 163.0 million Swiss francs in the first half of 2017, reflecting ~9% YoY growth at CER.

In the second quarter, Madopar reported revenues of 92.0 million Swiss francs, which reflected ~16% YoY growth at CER.

Ocrevus revenue trends

Roche’s Ocrevus generated revenues of 1.04 billion Swiss francs in the first half compared to 192.0 million Swiss francs in the first half of 2017.

In the second quarter, Ocrevus reported revenues of 561.0 million Swiss francs, which reflected ~195% YoY growth at CER. In the second quarter, in the United States and Europe, Ocrevus reported revenues of 496.0 million Swiss francs and 50.0 million Swiss francs, respectively. Ocrevus is presently approved in more than 60 countries.

In June, Roche presented data on long-term disability benefits of Ocrevus therapy in individuals with primary progressive multiple sclerosis. Roche also plans to initiate two new phase 3b trials, which are expected to evaluate the safety and efficacy of Ocrevus therapy in a wide range of individuals with progressive forms of multiple sclerosis.

The analysis of the extended control period of phase 3 ORATORIO trial in individuals with progressive forms of multiple sclerosis may be favorable for Ocrevus. Ocrevus showed to be clinically beneficial in delaying the time requirement of the wheelchair by seven years as measured by the duration until an individual reaches EDSS≥7 (Expanded Disability Status Scale seven or greater). Ocrevus therapy demonstrated a 46% decrease in the risk of disease progression to the requirement of wheelchair compared to placebo therapy.

Among Ocrevus’ peers, Biogen’s (BIIB) Tysabri and Novartis’ (NVS) Gilenya reported revenues of $467.0 million and $866.0 million, respectively, in the second quarter

Advertisement

More From Market Realist